Compositions and methods for treatment of chronic lung diseases
View Patent ↗Methods for treating, reducing, ameliorating or inhibiting symptoms idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia, comprising administering to a subject in need of an effective amount of a) multiple EGF-like-domains-9 (MEGF9) or a biologically active fragment thereof; b) uncoordinated receptor 5A (UNC5A) or a biologically active fragment thereof; c) dolichyl-phosphate beta-glucosyltransferase (ALG5) or a biologically active fragment thereof; d) a combination of two or three of a)-c); e) an antibody specifically binding to a); f) an antibody specifically binding to b); g) an antibody specifically binding to c); h) a combination of two or three of e)-g); or i) a combination of at least one of a)-c) and at least one of e)-g). Pharmaceutical compositions and processes for making and using the compositions are also disclosed.
1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a modified polypeptide, wherein the modified polypeptide is selected from the group consisting of:
a polypeptide consisting of the sequence of SEQ ID NO: 3 having at least one amino acid substitution or deletion in SEQ ID NO: 3 and at least 95% sequence identity to the SEQ ID NO: 3,
a polypeptide consisting of the sequence of SEQ ID NO: 4 in the form of a pharmaceutically acceptable salt, or a polypeptide consisting of the sequence of SEQ ID NO: 4 having a one amino acid or two-amino acid modification thereof, and
a polypeptide consisting of the sequence of SEQ ID NO: 102 having at least one amino acid substitution or deletion in SEQ ID NO: 102 and at least 96% sequence identity to SEQ ID NO: 102.
2. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 4 in the form of a pharmaceutically acceptable salt.
3. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 4 having a one-amino acid or two-amino acid modification thereof.
4. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 3 having at least one amino acid substitution or deletion in SEQ ID NO: 3 and at least 95% sequence identity to SEQ ID NO: 3.
5. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 4 having a two-amino acid modification thereof.
6. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 102 having at least one amino acid substitution or deletion in SEQ ID NO: 102 and at least 95% sequence identity to SEQ ID NO: 102.
7. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 4 having a one-amino acid modification thereof.
8. The pharmaceutical composition of claim 1 , wherein the modified polypeptide is the polypeptide consisting of the sequence of SEQ ID NO: 4 in the form of a pharmaceutically acceptable salt having a one-amino acid or two-amino acid modification thereof.